Drug Development
12 articles on Drug Development, written by Shotlee and medically reviewed for clinical accuracy.
AI Startup Acquires Parkinson's Cell Therapy from Ozempic Maker
Mark Zuckerberg-backed AI startup Cellular Intelligence has acquired global rights to STEM-PD, an experimental Parkinson's disease cell therapy developed by Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy. This strategic move signals a new era for AI in accelerating complex therapeutic development.
7 min read
Antimicrobial Peptides: A New Link to Neurodegenerative and Amyloid Diseases
Discover the groundbreaking research linking antimicrobial peptides (AMPs) to neurodegenerative and amyloid diseases. This article delves into the shared mechanisms, bidirectional feedback loops, and potential new therapeutic strategies emerging from this exciting field.
8 min read
Survodutide Shines: Dual GLP-1/Glucagon Agonist Shows Major Weight Loss
Zealand Pharma and Boehringer Ingelheim announced breakthrough Phase 3 results for survodutide, a dual GLP-1 and glucagon receptor agonist, demonstrating significant weight reduction and metabolic improvements in adults with obesity or overweight.
7 min read
Dr. Reddy's Semaglutide Inches Closer to Canadian Market Approval
Dr. Reddy's Laboratories has announced a significant milestone in its pursuit of bringing its semaglutide injection to the Canadian market, having received Drug Identification Numbers (DINs) from Health Canada. This development signals progress in the regulatory review process and underscores the company's commitment to expanding access to this important medication.
7 min read
GLP-1 Therapies: Risks and Rewards Across Conditions
GLP-1 therapies, including Ozempic (semaglutide) and Mounjaro (tirzepatide), have evolved from diabetes treatments to versatile options for weight management and cardiovascular health. While offering significant benefits like reduced appetite and vascular protection, they come with gastrointestinal side effects and rare serious risks. This guide evaluates their risks and rewards across conditions.
5 min read
The Quest for Oral GLP-1s: History and Innovations
For decades, GLP-1 receptor agonists like Ozempic have transformed diabetes and obesity treatment via injections, but patients crave oral options. This guide traces the scientific quest for oral GLP-1s, from early discoveries and Gila monster breakthroughs to Rybelsus challenges and promising algae-based innovations. Understand the barriers and what's next for affordable, pill-based metabolic health.
5 min read
Novo Nordisk's Extended Strategy with Weight Loss Medications Fuels Scientific Enthusiasm, Though Wall Street Remains Uneasy
Novo Nordisk has faced challenges with its stock and leadership due to the weight loss drug market. While scientists see potential in GLP-1 medications expanding beyond diabetes and obesity, investors are losing patience. Ongoing research highlights additional benefits like reducing cravings and aiding brain functions.
3 min read
GLP-1 Pills Are Coming: What You Should Know
Drug manufacturers are creating oral GLP-1 medications for obesity management. Injectable GLP-1 drugs like Ozempic have limitations, but pill versions offer a new option. One Wegovy pill is anticipated to receive FDA approval this year.
1 min read
Dr. Reddy's Semaglutide Expectations Hinged on Prompt Approvals
Dr. Reddy's Laboratories (DRL) is banking on semaglutide for future revenue, but faces challenges in securing timely approvals. The company aims to launch the drug domestically after patent expiration, while also navigating international regulatory hurdles.
2 min read
Optum Rx: Why Payers Should Monitor These 3 Pipeline Medications
A new Optum Rx report identifies three drugs targeting chronic conditions that are under review by the FDA. The medications address significant cost drivers for payers, including weight management and chronic inflammatory conditions.
4 min read
Ozempic 2.0 is Coming: A Potentially More Transformative Treatment
A new generation of weight loss medications is emerging, promising to be even more effective for human health. These include pills, more powerful injectables, and novel compounds that may have reduced side effects or require only monthly administration.
7 min read
Lilly's Eloralintide Obesity Drug Advances to Phase 3 Trials
Eli Lilly is progressing its experimental amylin obesity drug, eloralintide, into late-stage clinical trials following successful phase 2 study outcomes. The mid-stage study demonstrated significant weight loss in participants receiving the highest dose of the drug.
3 min read